Evidence map›Paper›PMID 41822815›Full record

ArticleSleep advances : a journal of the Sleep Research Society2026

Prevalence of diagnosed idiopathic hypersomnia among adults in the United States 2019-2023: analysis of healthcare claims.

Sarah C Markt, Jed Black, Richard K Bogan, Elizabeth T Jensen, Patricia Prince, Adina Estrin, Monica Iyer, Marisa Whalen, Jessica K Alexander, Weiyi Ni and 2 more

Abstract read
In one paragraph

Article in Sleep advances : a journal of the Sleep Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah C MarktJazz Pharmaceuticals, Palo Alto, CA, United States.
Jed BlackJazz Pharmaceuticals, Palo Alto, CA, United States.
Richard K BoganSchool of Medicine, University of South Carolina, Columbia, SC, United States.ORCID https://orcid.org/0000-0001-7043-2974
Elizabeth T JensenSchool of Medicine, Wake Forest University, Winston-Salem, NC, United States.ORCID https://orcid.org/0000-0003-2704-6634
Patricia PrinceAetion, Inc., New York, NY, United States.
Adina EstrinAetion, Inc., New York, NY, United States.
Monica IyerAetion, Inc., New York, NY, United States.
Marisa WhalenJazz Pharmaceuticals, Philadelphia, PA, United States.
Jessica K AlexanderJazz Pharmaceuticals, Palo Alto, CA, United States.
Weiyi NiJazz Pharmaceuticals, Palo Alto, CA, United States.
Adeniyi T TogunJazz Pharmaceuticals, Palo Alto, CA, United States.
David T PlanteSchool of Medicine and Public Health, University of Wisconsin, Madison, WI, United States.ORCID https://orcid.org/0000-0003-2619-5654

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Study Objectives: National prevalence estimates for idiopathic hypersomnia (IH) are difficult to obtain. This study estimated the diagnosed IH prevalence among US adults. Methods: Symphony Integrated Dataverse claims (01/2015-12/2023) were analyzed. Eligible patients were aged ≥18 years with at least one medical/prescription claim in the year of interest (2019-2023) and prior year. IH was defined by ≥1 medical claim with an IH diagnosis code. Prevalence was estimated among all eligible patients in two ways: annual (IH diagnoses during year of interest) and all-time (IH diagnoses looking back all-time in the database from 2015 through year of interest). Age- and sex-adjusted prevalence estimates were also calculated using the US Census Bureau. Results: Over 179, 182, 193, 205, and 198 million adults were assessed for diagnosed IH prevalence in each respective year 2019-2023. Unweighted annual prevalence of diagnosed IH from 2019 to 2023 was 12.1, 11.1, 11.0, 10.5, and 11.1 per 100 000 persons, respectively. Unweighted all-time lookback prevalence of diagnosed IH from 2019 to 2023 was 32.7, 37.3, 40.6, 43.3, and 49.0 per 100 000 persons, respectively. From 2019 to 2023, estimated standardized numbers of US adults diagnosed with IH were 30 563, 27 975, 27 859, 26 624, and 28 754 based on annual prevalence, and 82 027, 93 768, 101 766, 107 763, and 124 905 based on all-time prevalence. Conclusions: Annual prevalence estimates (i.e. proportions of individuals with diagnosed IH during each year of interest) remained consistent across the follow-up period, ranging from 10.5 to 12.1 per 100 000 persons, signifying the rarity of the diagnosis.

Indexed as

healthcare administrative claimsidiopathic hypersomniaprevalencereal-world evidenceretrospective studies

Identifiers

PMID41822815
PMCPMC12978637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.